CNS Pharmaceuticals, Inc. — Director's Dealing 2019

Nov 8, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: CNS Pharmaceuticals, Inc. (CNSP)
CIK: 0001729427
Period of Report: 2019-11-07

Reporting Person: Climaco John M (Director, Chief Executive Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	900000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to purchase common stock (right to buy)	$2.00	2029-06-28	Common Stock (439500)		Direct

Footnotes

F1: The issuer has the right to repurchase from the reporting person, at a purchase price of $0.01 per share, a pro rata portion of 50% of the shares based on the portion of the three-year term remaining in the reporting person's employment term, which was executed on September 1, 2017.

F2: The options set forth in this table vest in four equal annual installments succeeding the issuance date, or June 28, 2019, subject to the grantee's continued service to the Company on each vesting date.